Loxo Oncology has been granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for cancer treatment drug LOXO-292.

The medication is a selective rearranged during transfection (RET) inhibitor for the treatment of patients with advanced RET fusion-positive thyroid cancer who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options.